Tirzepatide Reverses Metabolic Damage in Menopausal Obese Diabetic Mice
Tirzepatide reversed weight gain and improved insulin, leptin, and adiponectin levels in a triple-challenge mouse model combining obesity, diabetes, and menopause.
Quick Facts
What This Study Found
The triple-challenge model (obesity + diabetes + ovariectomy) created the most severe metabolic dysfunction. Obese diabetic ovariectomized mice had more pronounced weight gain slopes than obese diabetic mice with intact ovaries.
Tirzepatide treatment produced negative allometric body weight slopes across treatment time, meaning weight declined consistently. Treated mice showed improved adiponectin (a beneficial fat hormone), insulin levels, and leptin levels. The drug effects were seen in both ovariectomized and sham groups.
Interactions were observed between diet × ovariectomy (affecting weight gain), diet × tirzepatide (affecting weight loss), and diet × ovariectomy × tirzepatide (affecting food intake).
Key Numbers
- 120 mice across multiple groups
- Diet: 12 weeks high-fat/high-sucrose
- Treatment: tirzepatide 10 nmol/kg SC daily for 4 weeks
- Tirzepatide: negative allometric body weight slopes (consistent weight loss)
- Improved: adiponectin, insulin, leptin levels
- Ovariectomy worsened weight gain beyond diet alone
How They Did This
Female C57BL/6 mice (3 months old) underwent bilateral ovariectomy or sham surgery. For 12 weeks, groups received control diet or high-fat/high-sucrose diet (120 mice total across groups). Then tirzepatide (10 nmol/kg subcutaneously daily) or vehicle was administered for 4 additional weeks. Allometric analysis was used to model body weight changes over time.
Why This Research Matters
Menopausal women are at high risk for obesity, insulin resistance, and type 2 diabetes due to estrogen loss. This triple-challenge model is more clinically relevant than simple obesity models. Showing that tirzepatide works even with the added challenge of estrogen loss suggests it could be particularly valuable for postmenopausal women with diabetes.
The Bigger Picture
Post-menopausal women face compounded metabolic risk from estrogen loss, weight gain, and insulin resistance. This study provides preclinical evidence that tirzepatide works even in this triple-challenge scenario.
What This Study Doesn't Tell Us
This was tested in mice. Ovariectomy in young mice does not perfectly model human menopause, which involves gradual hormonal changes over years. The tirzepatide dose (10 nmol/kg daily) may not directly translate to human dosing. Only 4 weeks of treatment was tested. The allometric analysis is useful for modeling weight trends but does not capture all metabolic endpoints. Human menopause involves more complex hormonal changes than simple estrogen loss.
Questions This Raises
- ?Does tirzepatide compensate for estrogen loss or work through independent mechanisms?
- ?Would human post-menopausal women show similar responses?
Trust & Context
- Key Stat:
- Triple-challenge model reversed Tirzepatide improved metabolic outcomes even in mice with the worst possible combination: obesity, diabetes, and estrogen deficiency
- Evidence Grade:
- Rated preliminary: well-designed animal study with multiple comparison groups, but ovariectomy in young mice doesn't perfectly model human menopause.
- Study Age:
- Published in 2024. Addresses an understudied population — post-menopausal women with obesity and diabetes.
- Original Title:
- The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.
- Published In:
- Diabetes, obesity & metabolism, 26(10), 4613-4621 (2024)
- Authors:
- Reis-Barbosa, Pedro H(2), Marcondes-de-Castro, Ilitch, Marinho, Thatiany S(2), Aguila, Marcia Barbosa, Mandarim-de-Lacerda, Carlos A
- Database ID:
- RPEP-09142
Evidence Hierarchy
Frequently Asked Questions
Does tirzepatide work for post-menopausal weight gain?
In mice, tirzepatide reversed weight gain even with the added metabolic stress of estrogen loss. Human studies in this population are needed.
Why is menopause relevant to diabetes treatment?
Estrogen loss during menopause worsens insulin resistance and promotes abdominal fat gain, making diabetes harder to control.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09142APA
Reis-Barbosa, Pedro H; Marcondes-de-Castro, Ilitch; Marinho, Thatiany S; Aguila, Marcia Barbosa; Mandarim-de-Lacerda, Carlos A. (2024). The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.. Diabetes, obesity & metabolism, 26(10), 4613-4621. https://doi.org/10.1111/dom.15820
MLA
Reis-Barbosa, Pedro H, et al. "The dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonist tirzepatide effects on body weight evolution, adiponectin, insulin and leptin levels in the combination of obesity, type 2 diabetes and menopause in mice.." Diabetes, 2024. https://doi.org/10.1111/dom.15820
RethinkPeptides
RethinkPeptides Research Database. "The dual glucose-dependent insulinotropic polypeptide/glucag..." RPEP-09142. Retrieved from https://rethinkpeptides.com/research/reis-barbosa-2024-the-dual-glucosedependent-insulinotropic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.